Pipeline

NeuClone is currently developing a deep pipeline of biosimilars across a variety of therapeutic indications. Ten of our biosimilar products are being co-developed in collaboration with Serum Institute of India. NeuClone is also developing an additional range of biosimilars independently.

 

The development stage of our first six products with Serum Institute are outlined below.

ORIGINATOR

Herceptin®
Trastuzumab

Stelara®
Ustekinumab

Prolia/XGEVA®

Denosumab

Synagis®

Palivizumab

Humira®

Adalimumab

Perjeta®

Pertuzumab

EARLY PRECLINICAL

LATE PRECLINICAL

PROCESS SCALE-UP

PHASE I

PHASE III

14 other products in development.

Herceptin
Trastuzumab

Early Preclinical

Late Preclinical

Process Scale-up

Phase 1 – 2018

Stelara
Ustekinumab

Early Preclinical

Late Preclinical

Process Scale-up

Phase 1 – 2019

Prolia/XGEVA
Denosumab

Early Preclinical

Late Preclinical

Phase 1 – 2019

Synagis
Palivizumab

Early Preclinical

Late Preclinical

Humira
Adalimumab

Early Preclinical

Late Preclinical

Learn more about what we do

Download NeuClone Brochure

 

Ellipse2_background-01